Expression of vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), contributes to angiogenesis that occurs during normal development and in many pathologic states, such as tumor growth and proliferative retinopathy. It has been known for some time that the expression of VEGF is controlled by oxygen tension.
1 2 Hypoxia upregulates the expression of VEGF in both cancer and ischemic retinal disease.
3 Under hypoxic conditions, expression of VEGF is also enhanced by stabilization of the mRNA
4 5 and by increased translation initiation at an internal ribosome entry site (IRE).
6 Environmental factors other than oxygen tension also control VEGF expression. For example, glucose deprivation increases expression of VEGF in HepG2 human hepatoma cells,
7 U-937 human monocytic cells,
8 and C6 rat glial tumor cells.
9 Three recent studies have implicated Ca
2+ in the control of VEGF expression. Höper et al.
10 demonstrated that A23187, a Ca
2+ ionophore, and thapsigargin, a sarcoendoplasmic Ca
2+-adenosine triphosphatase (ATPase) inhibitor, increased VEGF mRNA levels in a human monocytic cell line. In studies of the effects of basic fibroblast growth factor on VEGF secretion in osteoblast-like cells, Tokuda et al.
11 observed that A23187 and thapsigargin stimulated release of VEGF. Similarly, Metzen et al.
12 showed that thapsigargin stimulates VEGF secretion in human hepatoma cells.